Gilead Hits the Jackpot With HCV Drug

Gilead (NAS: GILD) just released data for a new hepatitis C combination therapy, and the results are staggering: a 100% cure rate! The news sent the stock soaring more than 13% on Monday. In this video, Motley Fool health care analyst Brenton Flynn breaks down the market potential for Gilead's new therapy and talks about another company with similarly excellent results that will want a share of that market for itself.

Gilead's story is an exciting one, and there is a lot of action in the stock price at the moment. But, while you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Gilead Hits the Jackpot With HCV Drug originally appeared on

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Motley Fool newsletter services recommend Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.